The additive effect of Eldecalcitol for glucocorticoid induced osteoporosis responding poorly to Alendronate

INTERVENTION: Alendronate (35mg/week) Alendronate (35mg/week) + Eldecalcitol (0.75mcg/day) CONDITION: glucocorticoid induced osteoporosis PRIMARY OUTCOME: Change from baseline to 12 months in lumbar spine BMD SECONDARY OUTCOME: Change from baseline to 12 months in total hip BMD; bone turnover markers (TRACP‐5b,uNTX, BAP, intact PTH, whole PTH, Sclerostin, OC, ucOC); incidence of fracture (vertebral fractures, non‐ vertebral fractures), ; blood calcium; urinary calcium; creatinine INCLUSION CRITERIA: 1. Glucocorticoid induced osteoporosis patients who satisfy one of any conditions as follows : A: patients whose lumbar spine or total hip BMD have not reached %YAM80 within 4 months. B: patients who have taken 5mg or more prednisolone per day. C: patients whose bone turnover markers have been beyond normal ranges. D: patients whose lumbar spine or total hip BMD have had negative change within 1 year. E: patients who have experienced at least an incident fracture while on bisphosphonates therapy 2. Patients with informed of consent.